What the trials showed
For most people, approved weight-loss injections are reasonably safe when prescribed and monitored by a clinician. They do have side effects, and a few rare risks need fast care.
The approved injections, Zepbound, Wegovy and Saxenda, were studied in large placebo-controlled trials. Stomach side effects were the most common, mostly mild to moderate, and most frequent while doses stepped up. Compare rates in side effects A to Z.
| Injection | Nausea on the label | Placebo |
|---|---|---|
| Zepbound 5 to 15 mg | 25% to 29% | 9% |
| Wegovy 2.4 mg | 44% | 16% |
| Saxenda 3 mg | 39% | 14% |
Most people in these trials stayed on treatment. A small share, roughly 4% to 7% depending on the trial and dose, stopped because of side effects, compared with about 3% on placebo.
When side effects tend to show up
Stomach effects usually show up in the days after starting or after a dose increase, then ease as your body adjusts. That's why every label steps the dose up slowly. If a step feels rough, your prescriber may wait longer before the next one. See a week-by-week picture with the side-effect timeline.
Explainer · 0:22
Read the transcript
- GLP-1 doses start low. Zepbound starts at 2.5 mg, a starter dose that gives your gut time to adjust.
- After at least 4 weeks, your prescriber may step it up by 2.5 mg, up to a maintenance dose of 5, 10 or 15 mg.
- Stomach side effects like nausea often flare for a few days after each increase, then settle on the same dose.
- Staying on a dose longer is common and allowed by the label. Never increase faster than your prescription says.
Rare but serious risks
- Pancreatitis: severe stomach pain that won't go away.
- Gallbladder problems, especially with rapid weight loss.
- Kidney problems from dehydration.
- Serious allergic reactions.
- A boxed warning about thyroid C-cell tumors seen in rodents.
- Food staying in the stomach during anesthesia: tell your surgical team.
Who shouldn't use them
People with a personal or family history of medullary thyroid carcinoma or MEN 2, anyone with a serious allergy to the medicine, and people who are pregnant. Severe stomach-emptying problems are another reason for caution. Details: Wegovy warnings and Zepbound warnings.
Who should be extra careful
- People taking insulin or a sulfonylurea, because low blood sugar becomes more likely.
- People with diabetic eye disease, since fast blood sugar changes have been linked to worsening retinopathy.
- People with kidney disease, who are more at risk if vomiting or diarrhea leads to dehydration.
- People with a history of depression, as the labels advise watching for mood changes.
- People using birth control pills with Zepbound. Tirzepatide can make the pill less effective, and the label advises a non-oral or added barrier method for 4 weeks after starting and after each dose increase. See GLP-1s, pregnancy and birth control.
Where the shot comes from
The FDA has warned about counterfeit pens, products sold without a prescription and compounded versions with dosing errors, especially vials measured in syringe units. An approved product from a licensed pharmacy is the safest starting point. More: compounded GLP-1s.
What to do if side effects hit
- Nausea: eat smaller meals, stop at the first sign of fullness, and choose bland, low-fat foods for a day or two. See nausea on GLP-1s.
- Constipation: add fluids and fiber slowly, and keep moving. See constipation.
- Diarrhea or vomiting: sip fluids often, and call your prescriber if you can't keep them down.
- Injection-site redness: rotate sites and let alcohol dry before injecting.
If side effects are hard to live with, tell your prescriber. They may slow the dose increases or keep you on a lower dose for longer.
Habits that make injections safer
- Follow the slow dose schedule: map yours.
- Drink steadily, especially when nauseous: dehydration tips.
- Eat enough protein: protein floor.
- Rotate injection sites and use a new needle or pen as directed.
- Tell every doctor, dentist and surgical team that you use a GLP-1.
What the research says on long-term safety
- Stronger evidence: semaglutide and liraglutide have years of data, including large heart-outcome trials in thousands of people. In the SELECT trial, Wegovy lowered the risk of heart attack, stroke and heart death by about 20% in adults with heart disease.
- Still being studied: the thyroid tumors seen in rodents haven't been confirmed in people, but studies can't fully rule out a risk. That's why the boxed warning remains.
- Newer data: tirzepatide was approved for weight in 2023, so its long-term record is shorter. Longer trials are ongoing.
When to talk to your doctor
- Severe stomach pain, sometimes spreading to your back.
- Vomiting or diarrhea that stops you keeping fluids down.
- Yellow skin or eyes, or pain under your right ribs.
- A lump in your neck, trouble swallowing or a hoarse voice that won't go away.
Run your numbers
Keep reading
Common questions
Are weight loss injections safe long term?
Semaglutide and liraglutide have years of data, including large heart-outcome trials. Long-term data keeps growing; regular check-ins with your prescriber matter.
What is the most common side effect of weight loss injections?
Nausea, followed by diarrhea, vomiting and constipation. They're most common during dose increases.
Are compounded weight loss injections safe?
Compounded drugs aren't FDA-approved or checked by the FDA for quality before sale, and the FDA has reported dosing errors.
Sources
- Jastreboff et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). NEJM 2022
- Wilding et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). NEJM 2021
- Pi-Sunyer et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management (SCALE). NEJM 2015
- FDA: concerns with unapproved GLP-1 drugs used for weight loss
- FDA: human drug compounding
Clinician review pending. Drafted from primary sources and waiting for sign-off by a licensed clinician (MD, DO or PharmD) before launch. Every number is checked against its source. Drug facts are re-checked quarterly, prices monthly and whenever a label changes. How we review · Report an error